Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 04 Jun 2022 Results assessing biomarker levels using serum samples of ankylosing spondylitis patients from following clinical studies: NCT02437162, NCT02438787, NCT0315828 and NCT02349061 presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 01 Dec 2021 Results assessing long-term efficacy and safety of ustekinumab through 2 years in patients with active systemic lupus erythematosus (SLE) published in The Journal of Rheumatology
    • 03 Oct 2020 Results assessing Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels, published in the Arthritis and Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top